Indo Us Bio-Tech Fined by NSE Amid Governance Concerns

Indo Us Bio-Tech Limited has paid a total fine of ₹0.0132 crore (₹1.32 lakh) to the National Stock Exchange (NSE) for non-compliance with certain SEBI (LODR) Regulations, 2015.

Reader Takeaway: Fine paid for governance lapse; other compliance gaps require management attention.

What just happened

The company incurred a fine from the NSE due to deficiencies in adhering to listing regulations. This included a base fine of ₹1.12 lakh, plus ₹0.2016 lakh in GST.

Why this matters

These compliance issues, particularly concerning the Audit Committee, related party transactions, and the absence of a Structured Digital Database (SDD), signal potential weaknesses in the company's internal controls and administrative oversight. While the immediate fine has been paid and a key committee reconstituted, these broader governance observations warrant attention from investors.

The backstory

An Annual Secretarial Compliance Report highlighted multiple non-compliance areas. The most significant was the Audit Committee's composition, which lacked the required number of independent directors from the listing date until November 21, 2024. Other issues included lapses in approving related party transactions (RPTs) and the non-implementation of an SDD for insider trading compliance.

What changes now

The company has taken corrective action by reconstituting the Audit Committee on November 22, 2024. Management attributes the Audit Committee lapse to unintentional delays in appointing independent directors. However, the other noted deficiencies, such as RPT approval processes and SDD maintenance, indicate areas that still require ongoing management focus and improvement.

Risks to watch

Investors should monitor the company's progress in fully implementing and maintaining the Structured Digital Database for insider trading compliance. Furthermore, ensuring proper prior approval for all related party transactions and maintaining thorough records for all board and committee activities, including CSR minutes, will be crucial.

Peer comparison

While specific peer data is not provided in the filing, robust compliance with SEBI's LODR regulations, including independent committee compositions and transparent transaction approvals, is a standard expectation for listed entities in India. Deviations can attract regulatory scrutiny and fines, impacting investor confidence.

Context metrics (time-bound)

• Fine Paid: ₹1.32 lakh to NSE.
• Audit Committee Reconstituted: November 22, 2024.
• Non-compliance Period (Audit Committee): From listing date until November 21, 2024.
• Reporting Period: Financial Year 2025-26.

What to track next

Investors should look for evidence of improved compliance processes in future secretarial audit reports, particularly regarding the implementation of the SDD and the handling of related party transactions. Consistent adherence to regulatory requirements will be key to rebuilding investor confidence.